Search
Annovis Bio Inc
ANVSAdd to Watchlist
1.965USD
+0.045+2.34%
Market hours （ET）Quotes delayed by 15 min
56.08MMarket Cap
LossP/E TTM
More Details of Annovis Bio Inc Company
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Annovis Bio Inc Info
Ticker SymbolANVS
Company nameAnnovis Bio Inc
IPO dateJan 29, 2020
CEOMaccecchini (Maria L)
Number of employees8
Security typeOrdinary Share
Fiscal year-endJan 29
Address101 Lindenwood Drive, Suite 225
CityMALVERN
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code19355
Phone14848753192
Websitehttps://www.annovisbio.com/
Ticker SymbolANVS
IPO dateJan 29, 2020
CEOMaccecchini (Maria L)
Company Executives of Annovis Bio Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
1.72M
+4.45%
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Dr. Cheng Fang, Ph.D.
Dr. Cheng Fang, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Ms. Eve Damiano
Ms. Eve Damiano
Senior Vice President - Regulatory
Senior Vice President - Regulatory
--
--
Ms. Melissa Gaines
Ms. Melissa Gaines
Senior Vice President - Clinical Operations
Senior Vice President - Clinical Operations
--
--
Dr. Mike Christie, Ph.D.
Dr. Mike Christie, Ph.D.
Vice President - Process Chemistry
Vice President - Process Chemistry
--
--
Mr. Mark P. Guerin, CPA
Mr. Mark P. Guerin, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
1.72M
+4.45%
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Dr. Cheng Fang, Ph.D.
Dr. Cheng Fang, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
FAQs
Who are the top five shareholders of Annovis Bio Inc?
The top five shareholders of Annovis Bio Inc are: Mr. Michael B. Hoffman
How many institutions hold shares of Annovis Bio Inc (ANVS)?
As of 2026Q1, 109 institutions hold shares of Annovis Bio Inc, with a combined market value of approximately 5.17M, accounting for 14.92% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1139662.00.